Vanessa Almendro, PhD, MBA 🟦

Vice President, Science and Technology. Head of Innovation at Danaher Corporation

Vanessa Almendro, PhD, MBA, is a prominent figure in the field of science and technology, currently serving as the Vice President of Science and Technology at Danaher Corporation. She has extensive experience in translational research and drug development, spanning over 18 years across various disease areas, including cancer.1 2

Education and Background

PhD from the University of Barcelona
Post-doctoral training at Dana-Farber Cancer Institute and Harvard Medical School
Executive MBA from MIT Sloan School of Management

Roles and Contributions

In addition to her position at Danaher, Almendro is a board member of the MIT Sandbox Innovation Fund Program, where she contributes to fostering innovation and entrepreneurship among students. She is also a Senior Principal and Co-Founder of the Brain Tumor Investment Fund, which aims to catalyze private sector investment in brain tumor research and treatment.1 3

Almendro's leadership extends to various initiatives aimed at bridging the gap between scientific research and practical applications in healthcare. Her work emphasizes the importance of innovative solutions in addressing complex health challenges.

Professional Affiliations

Board member at MIT Sandbox Innovation Fund Program
Senior Principal at Brain Tumor Investment Fund
Vice President at Danaher Corporation

Her multifaceted career reflects a commitment to advancing medical science through strategic leadership and innovation.

Highlights

Apr 17 · biospace.com

ORYZON Appoints Eisai Executive Vanessa Almendro Navarro to ...

Apr 17 · oryzon.com

ORYZON appoints Eisai executive Vanessa Almendro Navarro to ...

Experience

Vice President, Science and Technology, Head of Innovation at Danaher Corporation (June 2021 - Present)

Managing Partner and co-founder National Brain Tumor Society Investment Fund at National Brain Tumor Society (October 2019 - Present); Head of Strategy and External Innovation at Eisai Center for Genetics Guided Dementia Discovery (December 2019 - June 2021); Director, Strategy and Operations at Cogen Therapeutics, Inc. (November 2018 - November 2019); Research Fellow I, Head of the Exploratory Biology at Vertex Pharmaceuticals (2014 - October 2016)

Education

Bachelor in Biology from University of Barcelona (1996-2000); Ph.D. in Biochemistry and Molecular Biology, Summa cum laude from University of Barcelona (2000-2004); Post-doctoral training from Harvard Medical School (2008-2014); MBA from Massachusetts Institute of Technology (2017-2019)